Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2316)	4/1/2008 12:13:58 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MITI Is up 13.71% on low volume of 12,122 about 1/4 its ADV The stock needs to close above its March27-March28 double top at the $2.12 level before it can try to test the Jan22 spike at $2.42 bigcharts.marketwatch.com On Jan22 was when it announced the publication of a preclinical study in Cancer Research demonstrating that efficacious doses of a BiTE antibody targeting epithelial cell adhesion molecule EpCAM or CD326 were well tolerated in two mouse cancer models.(BiTE antibodies join cytotoxic T cells with cancer cells.) The stock trades around 2.85xBV with negativeCF around $0.45; the insiders reportedly hold >30% with the float around 20M & the short ratio around 8x its ADV MITI has been trimming its loss in the last 3Qs in spite of lower revenues in the last Q. The March 2004 H was $40.05 bigcharts.marketwatch.com Bernard